<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Nextcure Inc — News on 6ix</title>
    <link>https://6ix.com/company/nextcure-inc</link>
    <description>Latest news and press releases for Nextcure Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 07 Apr 2026 12:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/nextcure-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a50778dffbe2df10aea0.webp</url>
      <title>Nextcure Inc</title>
      <link>https://6ix.com/company/nextcure-inc</link>
    </image>
    <item>
      <title>NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-receives-fast-track-designation-for-sim0505-cdh6-adc-in-ovarian-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-receives-fast-track-designation-for-sim0505-cdh6-adc-in-ovarian-cancer</guid>
      <pubDate>Tue, 07 Apr 2026 12:05:00 GMT</pubDate>
      <description>The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be presented at ASCO 2026; dose optimization in ovarian cancer expected to begin in Q2 2026 BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies</description>
    </item>
    <item>
      <title>NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-and-simceres-sim0505-cdh6-adc-abstract-accepted-for-asco-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-and-simceres-sim0505-cdh6-adc-abstract-accepted-for-asco-2026-1</guid>
      <pubDate>Tue, 31 Mar 2026 20:05:00 GMT</pubDate>
      <description>The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company, today announced that an abstract for SIM0505 has been accepted for the America</description>
    </item>
    <item>
      <title>NextCure Provides Business Update and Reports Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-update-and-reports-full-year-2025-financial-results-66</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-update-and-reports-full-year-2025-financial-results-66</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026LNCB74</description>
    </item>
    <item>
      <title>NextCure Provides Business Update</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-120000556</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-120000556</guid>
      <pubDate>Fri, 23 Jan 2026 12:00:00 GMT</pubDate>
      <description>SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a preliminary year-end 2025 cash position. SIM0505 (CDH6 ADC): Phase 1 dose e</description>
    </item>
    <item>
      <title>NextCure Provides Business Update </title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-update</guid>
      <pubDate>Fri, 23 Jan 2026 05:00:00 GMT</pubDate>
      <description>SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts</description>
    </item>
    <item>
      <title>NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-present-piper-sandler-37th-130000397</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-present-piper-sandler-37th-130000397</guid>
      <pubDate>Thu, 20 Nov 2025 13:00:00 GMT</pubDate>
      <description>BELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City on Wednesday, December 3rd, at 11:00 am ET. A live audio webcast will be available through the Investors section of the company’s websit</description>
    </item>
    <item>
      <title>NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-announces-closing-21-5-130000621</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-announces-closing-21-5-130000621</guid>
      <pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
      <description>Extends cash runway into first half of 2027, beyond planned first half of 2026 proof of concept (“POC”) data readouts of SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC)Led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome Asset Management in a private placement of common stock priced at the market BELTSVILLE, Md., Nov. 17, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to trea</description>
    </item>
    <item>
      <title>NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-announces-21-5-million-130000819</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-announces-21-5-million-130000819</guid>
      <pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
      <description>BELTSVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced that it has entered into definitive agreements with the participation of certain institutional and accredited investors, including Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, LP., Exome Asset Management as well as other healthcare focused funds, for the purchase and sale of</description>
    </item>
    <item>
      <title>NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-reports-third-210500210</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-reports-third-210500210</guid>
      <pubDate>Wed, 05 Nov 2025 21:05:00 GMT</pubDate>
      <description>BELTSVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third quarter 2025 financial results. “We have made significant progress advancing our promising ADC programs,” said Michael Richman, NextCure’s president and CEO. “We recently began U.S. enrollment in the Phase 1 trial f</description>
    </item>
    <item>
      <title>NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-simcere-zaiming-announce-expansion-120500288</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-simcere-zaiming-announce-expansion-120500288</guid>
      <pubDate>Thu, 16 Oct 2025 12:05:00 GMT</pubDate>
      <description>First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, and Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), to</description>
    </item>
    <item>
      <title>NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-present-h-c-wainwright-110000988</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-present-h-c-wainwright-110000988</guid>
      <pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
      <description>BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York City on Monday, September 8th, at 4:00 pm ET. A live audio webcast will be available through the Investors section of the company’s</description>
    </item>
    <item>
      <title>NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-reports-second-200500113</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-reports-second-200500113</guid>
      <pubDate>Thu, 07 Aug 2025 20:05:00 GMT</pubDate>
      <description>Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter Currently in cohort 4 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancersPlan to provide SIM0505 and LNCB74 program updates by the fourth quarter of 2025, along with proof of concept data readouts in the first half of 2026 BELTSVILLE, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-st</description>
    </item>
    <item>
      <title>Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta</title>
      <link>https://6ix.com/company/nextcure-inc/news/preclinical-data-demonstrate-anti-siglec-15-treatment-improves-bone-microarchitecture-and-reduces-fracture-incidence-in-mice-with-moderate-to-severe-osteogenesis-imperfecta</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/preclinical-data-demonstrate-anti-siglec-15-treatment-improves-bone-microarchitecture-and-reduces-fracture-incidence-in-mice-with-moderate-to-severe-osteogenesis-imperfecta</guid>
      <pubDate>Thu, 24 Jul 2025 20:05:00 GMT</pubDate>
      <description>BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of new preclinical data in a well-established model of osteogenesis imperfecta (OI) demonstrating that treatment with NC605, a novel anti-Siglec-15 antibody, achieved improved bone microarchitecture and reduced fracture incidence compa</description>
    </item>
    <item>
      <title>NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-simcere-zaiming-announce-strategic-110500686</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-simcere-zaiming-announce-strategic-110500686</guid>
      <pubDate>Mon, 16 Jun 2025 11:05:00 GMT</pubDate>
      <description>NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rightsPhase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025Initial Phase 1 clinical data is expected in the first half of 2026NextCure also gains rights to Simcere Zaiming’s proprietary linker and payload for use in an ADC directed to a NextCure novel target; Simcere Zaiming will have rights to greater China BELTSVILLE, Md</description>
    </item>
    <item>
      <title>NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-ligachembio-present-trial-progress-200500914</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-ligachembio-present-trial-progress-200500914</guid>
      <pubDate>Thu, 29 May 2025 20:05:00 GMT</pubDate>
      <description>LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimizationThe study is currently enrolling in dose escalationPoster to be presented June 2, 2025, 1:30 pm-4:30 pm CT BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat canc</description>
    </item>
    <item>
      <title>NextCure Provides Business Update and Reports First Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-reports-first-200500735</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-reports-first-200500735</guid>
      <pubDate>Thu, 01 May 2025 20:05:00 GMT</pubDate>
      <description>Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025Plan to provide a proof of concept data readout in the first half of 2026Cash of approximately $55.9 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., May 01, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and</description>
    </item>
    <item>
      <title>NextCure to Present at 24th Annual Needham Virtual Healthcare Conference</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-present-24th-annual-needham-110000546</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-present-24th-annual-needham-110000546</guid>
      <pubDate>Fri, 04 Apr 2025 11:00:00 GMT</pubDate>
      <description>BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the we</description>
    </item>
    <item>
      <title>NextCure Provides Business Update and Reports Full Year 2024 Financial Results</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-reports-full-210500630</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-provides-business-reports-full-210500630</guid>
      <pubDate>Thu, 06 Mar 2025 21:05:00 GMT</pubDate>
      <description>Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today prov</description>
    </item>
    <item>
      <title>NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-announces-first-patient-dosed-in-the-phase-1-study-of-lncb74-b7-h4-adc-as-therapeutic-for-treating-multiple-cancers</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-announces-first-patient-dosed-in-the-phase-1-study-of-lncb74-b7-h4-adc-as-therapeutic-for-treating-multiple-cancers</guid>
      <pubDate>Fri, 10 Jan 2025 05:00:00 GMT</pubDate>
      <description>BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and</description>
    </item>
    <item>
      <title>NextCure Announces Acceptance of IND Application for LNCB74</title>
      <link>https://6ix.com/company/nextcure-inc/news/nextcure-announces-acceptance-of-ind-application-for-lncb74</link>
      <guid isPermaLink="true">https://6ix.com/company/nextcure-inc/news/nextcure-announces-acceptance-of-ind-application-for-lncb74</guid>
      <pubDate>Tue, 10 Dec 2024 05:00:00 GMT</pubDate>
      <description>LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences BELTSVILLE, Md., Dec. 10,</description>
    </item>
  </channel>
</rss>